158 related articles for article (PubMed ID: 17359908)
1. CD117 (c-kit) expression in human hepatocellular carcinoma.
Becker G; Schmitt-Graeff A; Ertelt V; Blum HE; Allgaier HP
Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):204-8. PubMed ID: 17359908
[TBL] [Abstract][Full Text] [Related]
2. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.
Eckel F; von Delius S; Mayr M; Dobritz M; Fend F; Hosius C; Schleyer E; Schulte-Frohlinde E; Schmid RM; Lersch C
Oncology; 2005; 69(5):363-71. PubMed ID: 16319507
[TBL] [Abstract][Full Text] [Related]
4. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
[TBL] [Abstract][Full Text] [Related]
6. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY; Fisher GA; So S; Tang C; Levitt L
Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-kit protooncogene in human hepatocellular carcinoma.
Chung CY; Yeh KT; Hsu NC; Chang JH; Lin JT; Horng HC; Chang CS
Cancer Lett; 2005 Jan; 217(2):231-6. PubMed ID: 15617841
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy?
Kostoula V; Khan K; Savage K; Stubbs M; Quaglia A; Dhillon AP; Hochhauser D; Caplin ME
Oncol Rep; 2005 Apr; 13(4):643-7. PubMed ID: 15756436
[TBL] [Abstract][Full Text] [Related]
11. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
12. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of c-kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma.
Lee ES; Han EM; Kim YS; Shin BK; Kim CH; Kim HK; Won NH; Yeom BW; Kim I; Leong AS
Am J Clin Pathol; 2005 Jul; 124(1):31-6. PubMed ID: 15923163
[TBL] [Abstract][Full Text] [Related]
15. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells.
Mansuroglu T; Baumhoer D; Dudas J; Haller F; Cameron S; Lorf T; Füzesi L; Ramadori G
Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1206-11. PubMed ID: 19491699
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
18. CD117/KIT expression in pancreatic adenocarcinoma.
Bateman AC; Judd M; Radenkovic D; Johnson CD
Pancreas; 2008 Jan; 36(1):76-9. PubMed ID: 18192885
[TBL] [Abstract][Full Text] [Related]
19. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
